OBJECTIVE: To estimate cancer outcome and outcome predictors of women with endometrial intraepithelial neoplasia (EIN). METHODS: Outcomes of women with first diagnosis of EIN ("index biopsy") were determined by follow-up pathology. Patient characteristics were correlated with EIN regression, EIN persistence, and progression to cancer. RESULTS: Fifteen percent (95% confidence interval [CI] 9.8-20.8%, 26 of 177) of index EIN biopsy samples had concurrent cancer. Of the women with cancer-free index EIN biopsy samples and follow-up by hysterectomy or more than 18 months of surveillance, 25% (95% CI 18.4-33.3%, 36 of 142) showed regression, 35% (95% CI 27.4-43.7%, 50 of 142) showed persistence, and 39% (95% CI 31.3-48.0%, 56 of 142) showed progression. Nonwhite ethnicity and progestin treatment reduced cancer outcomes (odds ratio [OR] 0.16, 95% CI 0.03-0.84 and OR 0.24, 95% CI 0.08-0.70, respectively), whereas body mass index greater than 25 increased malignant outcomes (body mass index 25 or higher, OR 3.05, 95% CI 1.10-8.45). CONCLUSION: Endometrial intraepithelial neoplasia confers a high risk of cancer, but individual patient outcomes cannot be predicted. Management should include exclusion of concurrent carcinoma and consideration of hysterectomy.
OBJECTIVE: To estimate cancer outcome and outcome predictors of women with endometrial intraepithelial neoplasia (EIN). METHODS: Outcomes of women with first diagnosis of EIN ("index biopsy") were determined by follow-up pathology. Patient characteristics were correlated with EIN regression, EIN persistence, and progression to cancer. RESULTS: Fifteen percent (95% confidence interval [CI] 9.8-20.8%, 26 of 177) of index EIN biopsy samples had concurrent cancer. Of the women with cancer-free index EIN biopsy samples and follow-up by hysterectomy or more than 18 months of surveillance, 25% (95% CI 18.4-33.3%, 36 of 142) showed regression, 35% (95% CI 27.4-43.7%, 50 of 142) showed persistence, and 39% (95% CI 31.3-48.0%, 56 of 142) showed progression. Nonwhite ethnicity and progestin treatment reduced cancer outcomes (odds ratio [OR] 0.16, 95% CI 0.03-0.84 and OR 0.24, 95% CI 0.08-0.70, respectively), whereas body mass index greater than 25 increased malignant outcomes (body mass index 25 or higher, OR 3.05, 95% CI 1.10-8.45). CONCLUSION:Endometrial intraepithelial neoplasia confers a high risk of cancer, but individual patient outcomes cannot be predicted. Management should include exclusion of concurrent carcinoma and consideration of hysterectomy.
Authors: Ming-Chieh Lin; Lesley Lomo; Jan P A Baak; Charis Eng; Tan A Ince; Christopher P Crum; George L Mutter Journal: Mod Pathol Date: 2008-09-19 Impact factor: 7.842
Authors: E Weiderpass; H O Adami; J A Baron; C Magnusson; R Bergström; A Lindgren; N Correia; I Persson Journal: J Natl Cancer Inst Date: 1999-07-07 Impact factor: 13.506
Authors: Jonathan L Hecht; Tan A Ince; Jan P A Baak; Heather E Baker; Maryann W Ogden; George L Mutter Journal: Mod Pathol Date: 2005-03 Impact factor: 7.842
Authors: Cornelia L Trimble; James Kauderer; Richard Zaino; Steven Silverberg; Peter C Lim; James J Burke; David Alberts; John Curtin Journal: Cancer Date: 2006-02-15 Impact factor: 6.860
Authors: George L Mutter; Richard J Zaino; Jan P A Baak; Rex C Bentley; Stanley J Robboy Journal: Int J Gynecol Pathol Date: 2007-04 Impact factor: 2.762
Authors: Koah Robin Vierkoetter; Laura A T Kagami; Hyeong Jun Ahn; David M Shimizu; Keith Y Terada Journal: Int J Gynecol Cancer Date: 2016-02 Impact factor: 3.437
Authors: Joanne Kotsopoulos; Kathryn L Terry; Elizabeth M Poole; Bernard Rosner; Megan A Murphy; Jonathan L Hecht; Christopher P Crum; Stacey A Missmer; Daniel W Cramer; Shelley S Tworoger Journal: Int J Cancer Date: 2013-03-13 Impact factor: 7.396
Authors: Ilene K Tsui; William C Dodson; Allen R Kunselman; Hongying Kuang; Feng-Juan Han; Richard S Legro; Xiao-Ke Wu Journal: BMJ Open Date: 2016-01-28 Impact factor: 2.692